Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 5 de 5
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
J Pharmacol Sci ; 131(1): 51-7, 2016 May.
Artigo em Inglês | MEDLINE | ID: mdl-27165707

RESUMO

An abnormally high serum phosphate level induces calcific aortic stenosis (CAS), which is characterized by ectopic valve calcification and stenosis of the orifice area. Inhibition of ectopic calcification is a critical function of any internal medical therapy for CAS disease. The aim of the present study was to investigate the inhibitory effects of several derivatives of evocarpine, methanolic extracts from the fruits of Evodia rutaecarpa Bentham (Japanese name: Go-Shu-Yu) on the high phosphate-induced calcification of human aortic valve interstitial cells (HAVICs) obtained from patients with CAS. High phosphate (3.2 mM) concentrations significantly increased the calcification of HAVICs after 7 days of culture. This calcification was completely inhibited in the presence of sodium phosphonoformate (PFA), a selective inhibitor of the type III sodium-dependent phosphate cotransporter (PiT-1). PiT-1 contributes to phosphate uptake, resulting in calcification. 1-Methyl-2-undecyl-4(1H)-quinolone (MUQ; 30-300 nM), but not evocarpine or its derivatives dihydroevocarpine and 1-methyl-2-nonyl-4(1H)-quinolone, inhibited the high phosphate-induced HAVICs calcification in a concentration-dependent manner. Although all of the evocarpine derivatives attenuated alkaline phosphatase activity, only MUQ also decreased PiT-1 gene expression with cellular PiT-1 protein diminution. These results suggest that MUQ mitigated high phosphate-induced HAVICs calcification by inhibiting PiT-1 gene expression.


Assuntos
Estenose da Valva Aórtica/metabolismo , Valva Aórtica/patologia , Calcinose/metabolismo , Quinolonas/farmacologia , Proteínas Cotransportadoras de Sódio-Fosfato Tipo III/antagonistas & inibidores , Idoso , Fosfatase Alcalina/genética , Fosfatase Alcalina/metabolismo , Valva Aórtica/citologia , Valva Aórtica/metabolismo , Células Cultivadas , Expressão Gênica/efeitos dos fármacos , Humanos , Pessoa de Meia-Idade , Fosfatos , Proteínas Cotransportadoras de Sódio-Fosfato Tipo III/genética , Proteínas Cotransportadoras de Sódio-Fosfato Tipo III/metabolismo
2.
Anticancer Res ; 34(11): 6527-35, 2014 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-25368255

RESUMO

BACKGROUND: The purpose of the present was to investigate whether the in vitro effects of gefitinib, an EGFR tyrosine kinase inhibitor, may regulate the expression of type III sodium phosphate Na/Pi co-transporters in an in vitro glioma model. MATERIALS AND METHODS: Proliferation studies, global native EGFR and phosphorylated EGFR expressions, phosphate transporter type III isoform 1(PiT1) expression and phosphate transport with 99mTc-(V)-DMSA radioligand were performed in G111 (grade II astrocytoma), U-87-MG (grade III astrocytoma) and G152 (grade IV glioblastoma) cells. RESULTS: Cells treated with gefitinib showed a significant decrease in proliferation in relation to EGFR and p-EGFR expression. Gefitinib also produced a decrease in phosphate transport mediated PIT1 expression at both the RNA and protein levels. CONCLUSION: The link between gefitinib acting on the EGFR and PiT1 regulation in these cancer cell lines was herein shown.


Assuntos
Antineoplásicos/farmacologia , Receptores ErbB/metabolismo , Glioblastoma/tratamento farmacológico , Quinazolinas/farmacologia , Proteínas Cotransportadoras de Sódio-Fosfato Tipo III/antagonistas & inibidores , Apoptose/efeitos dos fármacos , Western Blotting , Proliferação de Células/efeitos dos fármacos , Ensaio de Imunoadsorção Enzimática , Receptores ErbB/genética , Gefitinibe , Glioblastoma/metabolismo , Glioblastoma/patologia , Humanos , Gradação de Tumores , Fosfatos/metabolismo , Isoformas de Proteínas , RNA Mensageiro/genética , Reação em Cadeia da Polimerase em Tempo Real , Reação em Cadeia da Polimerase Via Transcriptase Reversa , Proteínas Cotransportadoras de Sódio-Fosfato Tipo III/genética , Proteínas Cotransportadoras de Sódio-Fosfato Tipo III/metabolismo , Células Tumorais Cultivadas
3.
J Surg Res ; 184(1): 6-9, 2013 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-23849774

RESUMO

BACKGROUND: The aortic valve interstitial cell (AVIC) has been implicated in the pathogenesis of calcific aortic stenosis. When appropriately stimulated, AVICs undergo a phenotypic change from that of a myofibroblast to that of a bone-forming-like cell. An elevated blood level of low-density lipoprotein (LDL) cholesterol is a clinical risk factor for aortic stenosis, and oxidized LDL (ox-LDL) cholesterol has been consistently found in calcified aortic valve leaflets. However, whether it plays a role in the pathogenesis of aortic stenosis is unknown. The process of aortic valve leaflet calcification has been associated with the deposition of calcium phosphate, mediated in part by the phosphate inorganic transporter 1 (PiT-1), a sodium-phosphate ion cotransporter. Therefore, we hypothesized that ox-LDL induces an osteogenic change in human AVICs marked by the induction of PiT-1. Using isolated human AVICs, the purpose of the present study was to examine the effect of ox-LDL on the expression of PiT-1 and the osteogenic factor bone morphogenetic protein 2 (BMP-2), which is a protein necessary for bone formation. METHODS: Human AVICs were isolated from nonstenotic aortic valves obtained from the explanted hearts of patients undergoing cardiac transplantation (n = 4) and grown in culture. The cells were treated with serum-free media, serum-free media with dimethyl sulfoxide (vehicle control), 40 µg/mL of ox-LDL, or 40 µg/mL of ox-LDL plus 2.5 mM phosphonoformate hexahydrate acid. Phosphonoformate hexahydrate acid is a competitive inhibitor of PiT-1 by mimicking inorganic phosphate. Cell lysis was performed at 24 h after treatment. Cell lysates were analyzed using immunoblot and densitometry for PiT-1 and BMP-2. Statistical analysis was performed using analysis of variance. P < 0.05 was significant. RESULTS: ox-LDL stimulation of AVICs induced an increase in PiT-1 and BMP-2. ox-LDL induced increased production of the phosphate transporter, PiT-1, and the osteogenic factor, BMP-2. Inhibition of PiT-1 with phosphonoformate hexahydrate acid prevented ox-LDL-induced BMP-2 expression. CONCLUSIONS: These data offer mechanistic insight into the pathogenesis of calcific aortic stenosis.


Assuntos
Estenose da Valva Aórtica/metabolismo , Valva Aórtica/metabolismo , Calcinose/metabolismo , Fosfatos de Cálcio/metabolismo , Lipoproteínas LDL/metabolismo , Proteínas Cotransportadoras de Sódio-Fosfato Tipo III/metabolismo , Adulto , Valva Aórtica/citologia , Valva Aórtica/efeitos dos fármacos , Valva Aórtica/patologia , Estenose da Valva Aórtica/epidemiologia , Estenose da Valva Aórtica/patologia , Proteína Morfogenética Óssea 2/metabolismo , Proteína Morfogenética Óssea 2/farmacologia , Calcinose/epidemiologia , Calcinose/patologia , Células Cultivadas , Foscarnet/farmacologia , Humanos , Lipoproteínas LDL/farmacologia , Masculino , Pessoa de Meia-Idade , Prevalência , Fatores de Risco , Transdução de Sinais/efeitos dos fármacos , Transdução de Sinais/fisiologia , Proteínas Cotransportadoras de Sódio-Fosfato Tipo III/antagonistas & inibidores
4.
PLoS One ; 8(1): e53393, 2013.
Artigo em Inglês | MEDLINE | ID: mdl-23308213

RESUMO

The regulation of phosphate (Pi) handling is crucial during calcification of the aortic valve. Gene profiling of Pi transporters revealed that VIC culture expresses SLC201A1/Pit1 and SLC20A2/Pit2. On exposure to a mineralizing medium (2 mM Pi), the expression of Pi transporters in VIC culture is increased several folds, with the highest magnitude for SLC20A1. By using siRNAs, we established that silencing SLC20A1 significantly reduced Pi-induced mineralization of VICs. In human pathological specimens, we found that the expression of SCL20A1 was increased in CAVD tissues compared to control non-mineralized aortic valves. Treatment of VIC culture with Pi promoted the loss of mitochondrial membrane potential (ΔΨm) and cytochrome c release within the cytosol, leading to apoptosis. Inhibition of Pi transporters with phosphonoformic acid (PFA) prevented Pi-mediated apoptosis of VICs. Moreover, we discovered that the level of the Akt-1 transcript is diminished in CAVD tissues compared with control valves. Accordingly, treatment with Pi caused a reduction of the Akt-1 transcript in VIC culture, and treatment with PFA or siRNA against SLC20A1 restored the level of Akt-1. Overexpression of Akt-1 (pCMVAkt-1) prevented both Pi-induced apoptosis and mineralization of VIC culture. These results strongly suggest that overexpression of SLC20A1 promotes apoptosis and mineralization by altering the level of Akt-1.


Assuntos
Calcinose/genética , Expressão Gênica/efeitos dos fármacos , Cardiopatias Congênitas/genética , Doenças das Valvas Cardíacas/genética , Fosfatos/farmacologia , Proteínas Proto-Oncogênicas c-akt/genética , Proteínas Cotransportadoras de Sódio-Fosfato Tipo III/genética , Idoso , Idoso de 80 Anos ou mais , Valva Aórtica/efeitos dos fármacos , Valva Aórtica/metabolismo , Valva Aórtica/patologia , Apoptose/efeitos dos fármacos , Doença da Válvula Aórtica Bicúspide , Calcinose/metabolismo , Calcinose/patologia , Células Cultivadas , Citocromos c/metabolismo , Células Endoteliais/efeitos dos fármacos , Células Endoteliais/metabolismo , Células Endoteliais/patologia , Feminino , Cardiopatias Congênitas/metabolismo , Cardiopatias Congênitas/patologia , Doenças das Valvas Cardíacas/metabolismo , Doenças das Valvas Cardíacas/patologia , Humanos , Masculino , Potencial da Membrana Mitocondrial/efeitos dos fármacos , Pessoa de Meia-Idade , Mitocôndrias/efeitos dos fármacos , Mitocôndrias/metabolismo , Fosfatos/metabolismo , Proteínas Proto-Oncogênicas c-akt/metabolismo , RNA Interferente Pequeno/genética , Transdução de Sinais/efeitos dos fármacos , Proteínas Cotransportadoras de Sódio-Fosfato Tipo III/antagonistas & inibidores , Proteínas Cotransportadoras de Sódio-Fosfato Tipo III/metabolismo
5.
Am J Physiol Cell Physiol ; 293(2): C606-20, 2007 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-17494632

RESUMO

Members of the SLC20 family or type III Na(+) -coupled P(i) cotransporters (PiT-1, PiT-2) are ubiquitously expressed in mammalian tissue and are thought to perform a housekeeping function for intracellular P(i) homeostasis. Previous studies have shown that PiT-1 and PiT-2 mediate electrogenic P(i) cotransport when expressed in Xenopus oocytes, but only limited kinetic characterizations were made. To address this shortcoming, we performed a detailed analysis of SLC20 transport function. Three SLC20 clones (Xenopus PiT-1, human PiT-1, and human PiT-2) were expressed in Xenopus oocytes. Each clone gave robust Na(+)-dependent (32)P(i) uptake, but only Xenopus PiT-1 showed sufficient activity for complete kinetic characterization by using two-electrode voltage clamp and radionuclide uptake. Transport activity was also documented with Li(+) substituted for Na(+). The dependence of the P(i)-induced current on P(i) concentration was Michaelian, and the dependence on Na(+) concentration indicated weak cooperativity. The dependence on external pH was unique: the apparent P(i) affinity constant showed a minimum in the pH range 6.2-6.8 of approximately 0.05 mM and increased to approximately 0.2 mM at pH 5.0 and pH 8.0. Xenopus PiT-1 stoichiometry was determined by dual (22)Na-(32)P(i) uptake and suggested a 2:1 Na(+):P(i) stoichiometry. A correlation of (32)P(i) uptake and net charge movement indicated one charge translocation per P(i). Changes in oocyte surface pH were consistent with transport of monovalent P(i). On the basis of the kinetics of substrate interdependence, we propose an ordered binding scheme of Na(+):H(2)PO(4)(-):Na(+). Significantly, in contrast to type II Na(+)-P(i) cotransporters, the transport inhibitor phosphonoformic acid did not inhibit PiT-1 or PiT-2 activity.


Assuntos
Fosfatos/metabolismo , Proteínas Cotransportadoras de Sódio-Fosfato Tipo III/metabolismo , Sódio/metabolismo , Proteínas de Xenopus/metabolismo , Animais , Arseniatos/metabolismo , Feminino , Foscarnet/farmacologia , Humanos , Concentração de Íons de Hidrogênio , Cinética , Lítio/metabolismo , Potenciais da Membrana , Microinjeções , Modelos Biológicos , Oócitos , Técnicas de Patch-Clamp , Radioisótopos de Fósforo , Radioisótopos de Sódio , Proteínas Cotransportadoras de Sódio-Fosfato Tipo III/antagonistas & inibidores , Proteínas Cotransportadoras de Sódio-Fosfato Tipo III/genética , Succímero/farmacologia , Sulfatos/metabolismo , Proteínas de Xenopus/antagonistas & inibidores , Proteínas de Xenopus/genética , Xenopus laevis
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...